The Department of Health and Human Services has dispatched experimental antibody treatments and diagnostic tools to the Democratic Republic of Congo to assist in containing a widening Ebola outbreak. This decision marks a significant shift in policy, as the U.S. had previously restricted the availability of certain experimental drugs like those from Mapp Biopharmaceutical primarily for American citizens. The outbreak, involving the Bundibugyo strain, has already resulted in hundreds of deaths and threatens to spread across regional borders. By providing these resources, U.S. health officials hope to stabilize the situation and prevent a global health emergency similar to the 2014 West Africa crisis. Concurrently, the CDC is working with local health ministries to scale up vaccination efforts using recently approved vaccines that have shown effectiveness in preventing the spread of related Ebola strains.
First published Mon, Jul 13, 2026 · Pitre Media Publication · Non-partisan editorial standard →
Verified against: reuters.com · cdc.gov